Body-mass index, prostate cancer-specific mortality and biochemical recurrence:A systematic review and meta-analysis - Abstract

Epidemiology, Harvard School of Public Health, 677 Huntington Avenue, Boston, MA 02115.

Increasing evidence suggested obesity, measured by body-mass index (BMI), was associated with prostate cancer-specific mortality, and its impact on biochemical recurrence was also inconclusive. We systematically searched MEDLINE, EMBASE and bibliographies of retrieved studies up to Jan 5th, 2010. We used random-effects meta-analysis to assess the relative risks (RR) of prostate cancer-specific mortality and biochemical recurrence associated with a 5 kg/m2 increase in BMI. Among the 6 population-based cohort studies in 1,263,483 initially cancer-free men, 6,817 prostate cancer deaths occurred; a 5kg/m2 increase in BMI was associated with 15% (RR 1.15, 95%CI 1.06-1.25, p< 0.01) higher risk of dying of prostate cancer. In the 6 post-diagnosis survival studies on 18,203 patients with 932 prostate cancer deaths, a 5kg/m2 increase in BMI was associated with 20% higher prostate cancer-specific mortality (RR 1.20, 95%CI 0.99-1.46, p=0.06). In the 16 studies which followed 26,479 prostate cancer patients after primary treatment, a 5kg/m2 increase in BMI was significantly associated with 21% increased risk of biochemical recurrence (RR 1.21, 95%CI 1.11-1.31 p< 0.01). Elevated BMI is associated with risk of prostate cancer-specific mortality in prospective cohort studies and biochemical recurrence in prostate cancer patients. Its association with prostate cancer-specific mortality in diagnosed patients needs to be further evaluated.

Written by:
Cao Y, Ma J.   Are you the author?

Reference: Cancer Prev Res (Phila). 2011 Jan 13. Epub ahead of print.
doi: 10.1158/1940-6207.CAPR-10-0229

PubMed Abstract
PMID: 21233290 Prostate Cancer Section